GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
GeoVax Labs, Inc. (GOVX) is rated D+ (1.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (F). The rating has held at D+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | D+ (1.8) | F (0.3) | F (0.3) | C+ (2.6) | D+ (1.5) |
| 2026-11-05 | A- (3.9) | D+ (1.8) | F (0.3) | F (0.4) | C+ (2.7) | D+ (1.8) |
| 2026-10-29 | B+ (3.7) | D+ (1.8) | F (0.3) | F (0.5) | C+ (2.7) | D+ (1.8) |
| 2026-10-22 | B+ (3.7) | C- (1.9) | F (0.3) | F (0.4) | C+ (2.6) | D+ (1.8) |
| 2026-10-15 | B+ (3.7) | D+ (1.8) | F (0.3) | F (0.5) | C+ (2.6) | D+ (1.8) |